Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRQR
stocks logo

PRQR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
6.09M
+25.53%
-0.117
+18.65%
5.53M
+3.38%
-0.139
+28.64%
5.10M
+10.26%
-0.140
+0.59%
Estimates Revision
The market is revising Downward the revenue expectations for ProQR Therapeutics N.V. (PRQR) for FY2025, with the revenue forecasts being adjusted by -20.86% over the past three months. During the same period, the stock price has changed by -13.47%.
Revenue Estimates for FY2025
Revise Downward
down Image
-20.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.14%
In Past 3 Month
Stock Price
Go Down
down Image
-13.47%
In Past 3 Month
Wall Street analysts forecast PRQR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRQR is 7.25 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast PRQR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRQR is 7.25 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.120
sliders
Low
4.00
Averages
7.25
High
12.00
Current: 2.120
sliders
Low
4.00
Averages
7.25
High
12.00
Evercore ISI
Outperform
maintain
$4 -> $5
2025-07-11
Reason
Evercore ISI
Price Target
$4 -> $5
2025-07-11
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on ProQR Therapeutics to $5 from $4 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
Oppenheimer
Andreas Argyrides
Outperform
downgrade
$15 -> $9
2025-05-13
Reason
Oppenheimer
Andreas Argyrides
Price Target
$15 -> $9
2025-05-13
downgrade
Outperform
Reason
Oppenheimer analyst Andreas Argyrides lowered the firm's price target on ProQR Therapeutics to $9 from $15 and keeps an Outperform rating on the shares following quarterly results. The firm notes lead program/AX-0810 for cholestatic diseases remains on track for a 2Q25 CTA submission followed by topline data in Q4 2025 from the healthy volunteers study. Oppenheimer expects clinical candidate selection in 2025 for AX-2402/Rett Syndrome and AX-2911/MASH followed by trial initiations and topline readouts in 2026. The firm sees ProQR's initial clinical data and 2025 RNA editing catalysts re-igniting investor interest. While its fundamental outlook remains intact, negative sector sentiment continues to weigh heavily on early clinical-stage companies with no clinical data, as such, Oppenheimer increases the discount rate from 30% to 40%.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$10 → $12
2025-03-14
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$10 → $12
2025-03-14
Maintains
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$4
2025-03-14
Reason
Chardan Capital
Keay Nakae
Price Target
$4
2025-03-14
Maintains
Strong Buy
Reason
Jones Trading
Catherine Novack
Strong Buy
Initiates
$11
2025-02-12
Reason
Jones Trading
Catherine Novack
Price Target
$11
2025-02-12
Initiates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$10
2024-12-12
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$10
2024-12-12
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for ProQR Therapeutics NV (PRQR.O) is -3.91, compared to its 5-year average forward P/E of -5.14. For a more detailed relative valuation and DCF analysis to assess ProQR Therapeutics NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.14
Current PE
-3.91
Overvalued PE
-2.53
Undervalued PE
-7.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.49
Undervalued EV/EBITDA
-4.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
78.44
Current PS
0.00
Overvalued PS
246.75
Undervalued PS
-89.87
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PRQR News & Events

Events Timeline

(ET)
2025-11-06
07:17:23
ProQR Therapeutics announces Q3 results: EUR 0.10, unchanged from last year
select
2025-10-20 (ET)
2025-10-20
08:04:40
ProQR Therapeutics Granted CTA Approval for AX-0810
select
2025-08-07 (ET)
2025-08-07
07:26:02
ProQR Therapeutics sees cash runway into mid-2027
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-24NASDAQ.COM
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading

  • Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.

  • Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.

  • General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.

  • Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.

[object Object]
Preview
9.0
10-23NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

  • Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

  • Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

  • Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

  • Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.

[object Object]
Preview
9.0
10-20Newsfilter
ProQR Secures CTA Approval for AX-0810 and Plans Virtual Investor and Analyst Event on November 3, 2025

  • ProQR's Clinical Trial Approval: ProQR Therapeutics has received authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 clinical trial of AX-0810, an investigational RNA editing oligonucleotide targeting NTCP, aimed at treating cholestatic diseases.

  • Upcoming Investor Event: ProQR will host a virtual event on November 3, 2025, to discuss the safety, pharmacokinetics, and biomarker roadmap for AX-0810, featuring presentations from ProQR management and Professor Henkjan J. Verkade, a key opinion leader in pediatric gastroenterology.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ProQR Therapeutics NV (PRQR) stock price today?

The current price of PRQR is 2.12 USD — it has increased 5.47 % in the last trading day.

arrow icon

What is ProQR Therapeutics NV (PRQR)'s business?

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).

arrow icon

What is the price predicton of PRQR Stock?

Wall Street analysts forecast PRQR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRQR is 7.25 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ProQR Therapeutics NV (PRQR)'s revenue for the last quarter?

ProQR Therapeutics NV revenue for the last quarter amounts to 2.92M USD, decreased -26.78 % YoY.

arrow icon

What is ProQR Therapeutics NV (PRQR)'s earnings per share (EPS) for the last quarter?

ProQR Therapeutics NV. EPS for the last quarter amounts to -0.10 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for ProQR Therapeutics NV (PRQR)'s fundamentals?

The market is revising Downward the revenue expectations for ProQR Therapeutics N.V. (PRQR) for FY2025, with the revenue forecasts being adjusted by -20.86% over the past three months. During the same period, the stock price has changed by -13.47%.
arrow icon

How many employees does ProQR Therapeutics NV (PRQR). have?

ProQR Therapeutics NV (PRQR) has 166 emplpoyees as of December 05 2025.

arrow icon

What is ProQR Therapeutics NV (PRQR) market cap?

Today PRQR has the market capitalization of 205.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free